首页> 外文期刊>Current cardiology reports. >Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions
【24h】

Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions

机译:接受经皮冠状动脉介入治疗的风险,获益和未解决问题的抗凝患者双重抗血小板治疗

获取原文
获取原文并翻译 | 示例
       

摘要

A commonly encountered scenario is the patient with atrial fibrillation (AF) on oral anticoagulation (OAC) who either develops an acute coronary syndrome or has to undergo percutaneous coronary intervention with stent placement. In such patients, separate indications suggest combining OAC and dual antiplatelet therapy (DAPT). This approach, however, increases the risk of bleeding as well as thromboembolic risk if bleeding does not occur. For optimal clinical results, the risks and benefits of all possible treatment options should be determined based on the best available data. This review provides an overview of the most recent data regarding the optimal treatment of AF patients with an indication for combined treatment with OAC and DAPT.
机译:常见的情况是口服抗凝(OAC)引起房颤(AF)的患者,其会发展为急性冠状动脉综合征或必须接受经支架置入的经皮冠状动脉介入治疗。在此类患者中,单独的适应症建议将OAC与双重抗血小板治疗(DAPT)结合使用。但是,如果不发生出血,这种方法会增加出血的风险以及血栓栓塞的风险。为了获得最佳的临床效果,应根据可获得的最佳数据确定所有可能治疗方案的风险和收益。这篇综述概述了有关AF患者最佳治疗的最新数据,并指出了OAC和DAPT联合治疗的适应症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号